Evidence map›Paper›PMID 25190079›Full record

ReviewCold Spring Harbor perspectives in biology2014

IL-6 in inflammation, immunity, and disease.

Toshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto

2 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2,705 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,705citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04598334 unknown statusnot on this mapstarted 2022, after this paper: background citation

Investigating the Inflammatory Cytokines and Cytokine Storm Among Bangladeshi Patients With COVID-19: a Prospective, Observational Study

TypeobservationalSponsorInternational Centre for Diarrhoeal Disease Research, BangladeshRan2022 to 2022Enrolled75ConditionsCytokine Storm, COVID-19
NCT07559435 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Diagnostic and Prognostic Utility of IL-6 and MMP-7 in Pediatric Immune Mediated Interstitial Lung Disease

Typeobservational_patient_registrySponsorSohag UniversityRan2026 to 2028Enrolled60ConditionsPediatric Immune Mediated Interstitial Lung DiseaseArmsIL-6 (interlukin 6), High-Resolution Computed Tomography (HRCT):, Pulmonary Function Tests (PFTs)
3 · Its place in the literature

Who cites it

2,705 citing papers in PubMed, 4 syntheses or guidelines pooled it, 4,801 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

2,645 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Toshio TanakaDepartment of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan Department of Immunopathology, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
Masashi NarazakiDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Tadamitsu KishimotoLaboratory of Immune Regulation, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
Osaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity. For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Various clinical trials have since shown the exceptional efficacy of tocilizumab, which resulted in its approval for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Moreover, tocilizumab is expected to be effective for other intractable immune-mediated diseases. In this context, the mechanism for the continual synthesis of IL-6 needs to be elucidated to facilitate the development of more specific therapeutic approaches and analysis of the pathogenesis of specific diseases.

Indexed as

Antibodies, Monoclonal, HumanizedGene Expression RegulationHumansInflammationInterleukin-6Models, ImmunologicalReceptors, Aryl HydrocarbonSignal TransductionAntibodies, Monoclonal, HumanizedInterleukin-6Receptors, Aryl Hydrocarbontocilizumab

Identifiers

PMID25190079
PMCPMC4176007
OpenAlexW2148658155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.